Primary and Secondary Features of Parkinson's Disease Improve with Strategic Exposure to Bright Light: A Case Series Study

References

• Andrade L AF, Lima J CG, Tufik S, Bertolucci P HF, Carlini E A. REM sleep deprivation in an experimental model of Parkinson's disease. Arq. Neuropsiquiatr. 1987; 45(3)224–230
   PubMedGoogle Scholar
• Antón‐Tay F. Melatonin: effects on brain function. Adv. Biochem Pharmacol. 1974; 11: 315–324
   PubMedGoogle Scholar
• Antón‐Tay F, Diaz J L, Fernandez‐Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci. 1971; 10(Part 1)841–850
   Google Scholar
• Arieti S. The pineal gland in old age. J. Neuropathol. Exp. Neurol. 1954; 13: 482–491
   PubMed Web of Science ®Google Scholar
• Arnulf I, Konofal E, Merino‐Andreu M, Hoveto J L, Mesnage V, Welter M L, Lacomblez L, Golmard J L, Derenne J P, Agid Y. Parkinson's disease and sleepiness; an integral part of PD. Neurology. 2002; 58: 1019–1024
   PubMed Web of Science ®Google Scholar
• Artemenko A R, Levin Y I. Light therapy of patients with Parkinsonism. Zh. Nevropatol. Psikhiatr. Im. SS Korsakova. 1996; 96: 63–66
   PubMedGoogle Scholar
• Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo‐controlled trial. J. Clin. Psychiatry. 2003; 64: 648–653
   PubMed Web of Science ®Google Scholar
• Bertolucci P HF, Andrade L AF, Lima J GC, Carlini E A. Total sleep deprivation and Parkinson's disease. Arq. Neuropsychiatr. 1987; 45: 224–230
   PubMedGoogle Scholar
• Bordet R, Devos D, Brique S, Touitou Y, Guieu J D, Libersa C, Dustee A. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 2003; 26: 65–72
   PubMed Web of Science ®Google Scholar
• Brainard G C, Lewy A J, Menaker M, Fredrickson R H, Miller L S, Weleber R J, Cassone V, Hudson D. Dose response relationship between light iridescence and the suppression of melatonin in human volunteers. Brain Res. 1988; 454: 212–218
   PubMed Web of Science ®Google Scholar
• Bruguerolle B, Simon N. Biological rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin. Neuropharmacol. 2002; 25: 194–201
   PubMed Web of Science ®Google Scholar
• Burton J L, Cartlidge M, Schuster S. Effect of L‐Dopa on the seborrhea of Parkinsonism. Lancet 1970; 4: 19–20
   Google Scholar
• Burton J L, Cartlidge M, Schuster S. Effect of L‐Dopa on the seborrhea of Parkinsonism. Br. J. Dermatol. 1973; 88: 475–479
   PubMed Web of Science ®Google Scholar
• Burton S, Daya S, Potgeiter B. Melatonin modulates apomorphine‐induced rotational behaviour. Experientia 1991; 47: 466–469
   PubMedGoogle Scholar
• Catala M D, Canete‐Nicolas C, Iradi A, Tarazona P J, Tormos J M, Pascual‐Leone A. Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. 1997; 32: 553–558
   PubMed Web of Science ®Google Scholar
• Cotzias G C, Papavasiliou P S, Ginos J, Steck A, Düby S. Metabolic modification of Parkinson's disease and chronic manganese poisoning. Ann. Rev. Med. 1971; 22: 305–326
   PubMed Web of Science ®Google Scholar
• Daramola G F, Olowu A O. Physiological and radiological implications of a low incidence of pineal calcification in Nigeria. Neuroendocrinology 1972; 9: 41–57
   PubMed Web of Science ®Google Scholar
• Demet E M, Chicz‐Demet A, Fallon J H, Sokolski K N. Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999; 23: 753–784
   PubMed Web of Science ®Google Scholar
• Deniker P, Ginistet D, Loo H. Psychotropic drugs and mechanisms of mood regulation. Encephale 1975; 1: 359–362
   PubMedGoogle Scholar
• Douyon R, Serby M, Klutchko B, Rutrosen J. ECT and Parkinson's disease revisited: a naturalistic study. Am. J. Psychiatr. 1989; 146(11)1451–1455
   PubMed Web of Science ®Google Scholar
• Duvoisin R C, Golbe L I, Lepore F E. Progressive subnuclear palsy. Can. J. Neurol. Sci. 1987; 14: 547–554
   PubMed Web of Science ®Google Scholar
• Feldman R G. Parkinson's disease: individualizing therapy. Hospital Practice 1985; 20: 185, 80a–e, i, m, p, u
   Web of Science ®Google Scholar
• Fertl E, Auff E, Dopplebauer A, Waldhauser F. Circadian secretion pattern of melatonin in Parkinson's disease. J. Neural. Transm. 1991; 3: 41–47
   Web of Science ®Google Scholar
• Fertl E, Auff E, Dopplebauer A, Waldhauser F. Circadian secretion pattern of melatonin in novo Parkinson's patient. Evidence for phase shifting properties of l‐dopa. J. Neural Transm. 1993; 5: 227–234
   Web of Science ®Google Scholar
• Fonda D. Parkinson's disease in the elderly: psychiatric manifestations. Geriatrics 1985; 40: 109–112
   PubMed Web of Science ®Google Scholar
• Gerbaldo H, Cassady S, Maurer K, Pieschl D. The assessment of light intensity preference in psychiatric patients. Acta. Psychiatr Scand. 1997; 95: 236–241
   PubMed Web of Science ®Google Scholar
• Girotti F, Carella F, Grassi M P, Solveri P, Marano R, Caraceni T. Motor and cognitive performance of Parkinson's patients in the on and off phases of the disease. J. Neurol. Neurosurg Psychiatr. 1986; 49: 657–660
   PubMed Web of Science ®Google Scholar
• Hasegawa A, Ahtsubo K, Mori W. Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsies. Brain Res. 1987; 409: 343–349
   PubMed Web of Science ®Google Scholar
• Horne J A, Donlon J, Arendt J. Green light attenuates melatonin output and sleeplessness during sleep deprivation. Sleep. 1991; 14: 233–240
   PubMed Web of Science ®Google Scholar
• Jeanneau A. Electroconvulsive therapy in the treatment of Parkinson's disease. Encephale 1993; 19: 573–578
   PubMedGoogle Scholar
• Karesek M. Melatonin in humans where we are 40 years after its discovery. Neurosci. Lett. 1999; 20: 179–188
   Google Scholar
• Kendall B, Cavanagh N. Intracranial calcification in paediatric computed tomography. Neuroradiology 1986; 28: 324–330
   PubMed Web of Science ®Google Scholar
• Krahn L E, Gleber E Rummans TA, Pileggi T S, Lucas D L, Li H. The effects of electroconvulsive therapy on melatonin. JECT 2000; 16: 391–398
   Google Scholar
• Krstic R. Pineal calcification: its mechanism and significance. J Neural Transm. 1986, Suppl. 21: 415–432
   Google Scholar
• Kunz D, Bes F Schlattmann P, Herrmann W M. On pineal calcification and its relation to subjective sleep perception: a hypothesis driven pilot study. Psychiatr. Res. 1998; 82: 187–191
   PubMed Web of Science ®Google Scholar
• Kuzuhara S. Drug induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Neurol. 2001; 248(Suppl. 3)28–31
   Google Scholar
• Larsen T A, Calne S, Calne D B. Assessment of Parkinson's disease. Clin. Neuropharmacol. 1984; 7: 165–169
   PubMedGoogle Scholar
• Lewy A J, Wehr T Z, Goodwin F K, Newsome D A, Markey S P. Light suppresses melatonin secretion in humans. Science 1980; 210: 1267–1269
   PubMed Web of Science ®Google Scholar
• Likert R A. A technique for the measurements of attitudes. Arch. Psych. 1932, No. 140
   Google Scholar
• Maietta G, Rongioletti F, Rebora A. Seborrheic dermatitis and daylight. Acta Derm. Veneroel 1991; 71: 538–593, (Stock).
   PubMed Web of Science ®Google Scholar
• Martiny K. Adjunctive bright light in non‐seasonal major depression. Acta Psychiatr. Scand. Suppl. 2004; 425: 7–28
   Google Scholar
• Mayo J C, Sainz R M, Uria H, Antolin I, Esteban M M, Rodriguez C. Melatonin prevents apoptosis induced by 6‐hydroxydopamine in neuronal cells: implications for Parkinson's disease. J. Pin. Res. 1998; 24: 179–92
   PubMed Web of Science ®Google Scholar
• Meco G, Bonifati V, Bedin L, Bellatreccia A, Vanacoe N, Franzese A. Relations between on‐off phenomena and cognitive function in Parkinson's disease. Ital. J. Neurol. Sci. 1991; 12: 57–62
   PubMedGoogle Scholar
• Okudera H, Hara H, Kobayashi S, Akada T, Shimizu K. Evaluation of the intracranial calcification associated with aging on computed tomography. Brain and Nerve. 1986; 38: 129–133
   PubMedGoogle Scholar
• Okun M S, Watts R L. Depression associated with Parkinson's disease. Clinical factors and treatment. Neurology. 2002; 58(Suppl. 1)S63–S70
   PubMedGoogle Scholar
• Old V, Firm I N. Parameters of normality in a geriatric population. Arch. Int. Med. 1974; 132: 101–132
   Google Scholar
• Papavasiliou P S, Cotzias G C, Düby S E, Steck A J, Bell M, Lawrence W H. Melatonin and Parkinsonism. JAMA. 1972; 221(1)88–89
   PubMed Web of Science ®Google Scholar
• Partinen M. Sleep disorders related to Parkinson's disease. J. Neurology. 1997; 224: S3–S6
   Google Scholar
• Patterson A J, Vickers C. Sex and strain related effects of melatonin and 5‐methoxytryptophol on open filed behaviour in paired mice. Behav. Brain. Res. 1984; 13: 107–113
   PubMed Web of Science ®Google Scholar
• Price L H, Spencer D D, Marek K L, Robbins R J, Leranth C, Farhi A, Naftolin F, Roth R H, Bunney B S, Hoffer P B, Makuck R, Redmond D E. Psychiatric status after foetal mesencephalic tissue transplantation in Parkinson's disease. Biol. Psychiatr. 1995; 38: 498–505
   PubMed Web of Science ®Google Scholar
• Ralph C L. Correlations of melatonin content in pineal gland, blood and brain of some birds and mammals. Am. Zool. 1976; 16: 35–43
   Google Scholar
• Reist C, Sokolski K N, Chen C C, Koskinas E, Demet E M. The effect of sleep deprivation on motor impairment and retinal adaptation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatr. 1995; 19: 445–454
   PubMed Web of Science ®Google Scholar
• Reiter R J. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 1998; 56: 359–384
   PubMed Web of Science ®Google Scholar
• Rosenthal N E, Sack D A, Gillen J C, Lewy A J, Goodwin F K, Davenport Y, Mueller P S, Newsome D A, Wehr T A. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatr. 1984; 41: 72–80
   PubMed Web of Science ®Google Scholar
• Rosenthal N E, Jacobson F M, Sack D A, Arendt J, James S P, Parry B L, Wher T A. Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am. J. Psychiatr. 1988; 145: 52–56
   PubMed Web of Science ®Google Scholar
• Roth W, Wurtman R J, Altschule M D. Morphological changes in the pineal parenchyma cells exposed to continuous light or darkness. Endocrinology 1962; 71: 888–892
   PubMed Web of Science ®Google Scholar
• Sandyk R. Mechanisms of action of ECT in Parkinson's disease: possible role of pineal melatonin. Int. J. Neurosci. 1990; 50: 83–94
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on‐off” phenomenon. Int. J. Neurosci. 1992a; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. Successful treatment of multiple sclerosis with magnetic fields. Int. J. Neurosci. 1992b; 66: 237–250
   PubMed Web of Science ®Google Scholar
• Sartucci F, Orlandi G, Lucetti C, Bonuccelli U, Murri L, Orsini C, Porciatti V. Changes in pattern electroretinograms to equiluminate red‐green and blue‐yellow gratings in patients with early Parkinson's disease. J. Clin. Neurophysiol. 2003; 20: 375–381
   PubMed Web of Science ®Google Scholar
• Schnaberth G. Depression and Parkinson syndrome. Wein. Med. Wochenschr. 1986; 136(15–16)391–393
   PubMed Web of Science ®Google Scholar
• Shaw K M. Hypothalamo‐pituitary‐adrenal function in Parkinsonian patients and patients treated with melatonin. Curr. Med. Res. Op. 1977; 4: 743–746
   Web of Science ®Google Scholar
• Shaw K M, Stern G M, Sandler M. Melatonin and Parkinsonism. Lancet 1973; 1: 271
   PubMed Web of Science ®Google Scholar
• Shaw K M, Stern G M, Sandler M. Melatonin and metatyrosine in the treatment of Parkinsonism. Adv. Neurol. 1975; 3: 115
   Google Scholar
• The Parkinson Archive Treasures Pieno Parkinson. An international email list and website about Parkinson's disease. 1995, http://www.parkinsons-information-information-exchange-network-online.com/, Accessed June 2006
   Google Scholar
• Toutiou Y, Smolensky M H, Portaluppi F. Ethics, standards, and procedures of animal and human chronobiology research. Chronobiol. Int. 2006; 23: 1083–1096
   PubMed Web of Science ®Google Scholar
• Verschoore M, Ortonne J P. Seborrheic dermatitis and daylight. Acta Derm. Venereol. 1993; 73: 396
   PubMed Web of Science ®Google Scholar
• Welker H A, Semm P, Willig R P, Commentz J C, Wiltschko W, Vollrath L. Effects of artificial magnetic field on serotonin‐N‐acetyltransferase activity and melatonin content of the rat pineal gland. Exp. Brain. Res. 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Willis G L. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function. Behav. Brain. Res. 2005; 160: 148–160
   PubMed Web of Science ®Google Scholar
• Willis G L, Armstrong S M. Orphan neurones and amine access: the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res. Rev. 1998; 27: 177–242
   PubMedGoogle Scholar
• Willis G L, Armstrong S M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. 1999; 66: 785–795
   PubMed Web of Science ®Google Scholar
• Willis G L, Kennedy G A. The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease. Rev. Neurosci. 2004; 15: 75–87
   PubMed Web of Science ®Google Scholar
• Willis G L, Robertson A D. Recovery of experimental Parkinson's disease with the melatonin analogues ML‐23 and S‐20928 in a chronic, bilateral 6‐OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmac. Biochem. Behav. 2004; 70: 413–429
   Google Scholar
• Willis G L, Robertson A D. Recovery from experimental Parkinson's disease in the 1‐methyl‐4‐phenyl, 1,2,3,6 tetrahydropyridine hydrochloride (MPTP) treated marmoset with the melatonin analogue ML‐23. Pharmac. Biochem. Behav. 2005; 80: 9–26
   PubMed Web of Science ®Google Scholar
• Wright H R, Lack L C. Effect of light wavelength on suppression and phase delay of the melatonin rhythm. Chronobiol. Int. 2001; 18: 801–808
   PubMed Web of Science ®Google Scholar
• Wright H R, Lack L C, Partridge K J. Light emitting diodes can be used to phase delay the melatonin rhythm. J. Pineal. Res. 2001; 31: 350–355
   PubMed Web of Science ®Google Scholar
• Wurtman R J, Axelrod J. The formation metabolism and physiologic effects of melatonin in mammals. Prog. Brain. Res. 1965; 10: 520–529
   PubMedGoogle Scholar
• Wurtman R J, Axelrod J, Barchas J D. Age and enzyme activity in the human pineal. J. Clin. Endocrin. 1964; 24: 299–301
   PubMed Web of Science ®Google Scholar
• Zimmerman R A, Bilaniuk L T. Age related incidence of pineal calcification detected by computed tomography. Radiology. 1982; 142: 659–662
   PubMed Web of Science ®Google Scholar
• Zisapel N. Melatonin‐dopamine interactions: from basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 2001; 21: 605–616
   PubMed Web of Science ®Google Scholar